The cell surface estrogen receptor, G protein-coupled receptor 30 (GPR30), is markedly down regulated during breast tumorigenesis
I Poola, J Abraham, A Liu… - Breast cancer: basic …, 2008 - journals.sagepub.com
I Poola, J Abraham, A Liu, JJ Marshalleck, RL DeWitty
Breast cancer: basic and clinical research, 2008•journals.sagepub.comBackground GPR30 is a cell surface estrogen receptor that has been shown to mediate a
number of non-genomic rapid effects of estrogen and appear to balance the signaling of
estrogen and growth factors. In addition, progestins appear to use GPR30 for their actions.
Therefore, GPR30 could play a critical role in hormonal regulation of breast epithelial cell
integrity. Deregulation of the events mediated by GPR30 could contribute to tumorigenesis.
Methods To understand the role of GPR30 in the deregulation of estrogen signaling …
number of non-genomic rapid effects of estrogen and appear to balance the signaling of
estrogen and growth factors. In addition, progestins appear to use GPR30 for their actions.
Therefore, GPR30 could play a critical role in hormonal regulation of breast epithelial cell
integrity. Deregulation of the events mediated by GPR30 could contribute to tumorigenesis.
Methods To understand the role of GPR30 in the deregulation of estrogen signaling …
Background
GPR30 is a cell surface estrogen receptor that has been shown to mediate a number of non-genomic rapid effects of estrogen and appear to balance the signaling of estrogen and growth factors. In addition, progestins appear to use GPR30 for their actions. Therefore, GPR30 could play a critical role in hormonal regulation of breast epithelial cell integrity. Deregulation of the events mediated by GPR30 could contribute to tumorigenesis.
Methods
To understand the role of GPR30 in the deregulation of estrogen signaling processes during breast carcinogenesis, we have undertaken this study to investigate its expression at mRNA levels in tumor tissues and their matched normal tissues. We compared its expression at mRNA levels by RT quantitative real-time PCR relative to GAPDH in ERα”—positive (n = 54) and ERα”—negative (n = 45) breast cancer tissues to their matched normal tissues.
Results
We report here, for the first time, that GPR30 mRNA levels were significantly down-regulated in cancer tissues in comparison with their matched normal tissues (p < 0.0001 by two sided paired t-test). The GPR30 expression levels were significantly lower in tumor tissues from patients (n = 29) who had lymph node metastasis in comparison with tumors from patients (n = 53) who were negative for lymph node metastasis (two sample t-test, p < 0.02), but no association was found with ERα, PR and other tumor characteristics.
Conclusions
Down-regulation of GPR30 could contribute to breast tumorigenesis and lymph node metastasis.
Sage Journals